NAD(P)H:Quinone oxidoreductase activity is the principal determinant of beta-lapachone cytotoxicity.
about
Potential mechanism of phytochemical-induced apoptosis in human prostate adenocarcinoma cells: Therapeutic synergy in genistein and beta-lapachone combination treatmentNAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinonesModulating endogenous NQO1 levels identifies key regulatory mechanisms of action of β-lapachone for pancreatic cancer therapy.Beta-lapachone suppresses radiation-induced activation of nuclear factor-kappaBRedox regulation of mitochondrial functionMitochondrial targeted β-lapachone induces mitochondrial dysfunction and catastrophic vacuolization in cancer cellsA chemical genetic screen for modulators of asymmetrical 2,2'-dimeric naphthoquinones cytotoxicity in yeastDistinct genes related to drug response identified in ER positive and ER negative breast cancer cell linesMolecular resistance fingerprint of pemetrexed and platinum in a long-term survivor of mesotheliomaSulindac compounds facilitate the cytotoxicity of β-lapachone by up-regulation of NAD(P)H quinone oxidoreductase in human lung cancer cellsFeatures of idebenone and related short-chain quinones that rescue ATP levels under conditions of impaired mitochondrial complex INQO1-dependent redox cycling of idebenone: effects on cellular redox potential and energy levelsNuclear clusterin/XIP8, an x-ray-induced Ku70-binding protein that signals cell death.β-lapachone significantly increases the effect of ionizing radiation to cause mitochondrial apoptosis via JNK activation in cancer cells.E1B and E4 oncoproteins of adenovirus antagonize the effect of apoptosis inducing factorIntratumoral delivery of beta-lapachone via polymer implants for prostate cancer therapyTumor-selective, futile redox cycle-induced bystander effects elicited by NQO1 bioactivatable radiosensitizing drugs in triple-negative breast cancers.Beta-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy.Endoplasmic reticulum stress-induced JNK activation is a critical event leading to mitochondria-mediated cell death caused by β-lapachone treatment.β-Lapachone induces heart morphogenetic and functional defects by promoting the death of erythrocytes and the endocardium in zebrafish embryosProdrug strategy to achieve lyophilizable, high drug loading micelle formulations through diester derivatives of β-Lapachone.Beta-lapachone, a modulator of NAD metabolism, prevents health declines in aged mice.Regulation of p53 stability and p53-dependent apoptosis by NADH quinone oxidoreductase 1Selective killing of cancer cells by beta -lapachone: direct checkpoint activation as a strategy against cancer.The curcuminoid CLEFMA selectively induces cell death in H441 lung adenocarcinoma cells via oxidative stress.Photophysics and photochemistry of the β-lapachone derived diphenyldihydrodioxin: generation and characterization of its cation radical.SoNar, a Highly Responsive NAD+/NADH Sensor, Allows High-Throughput Metabolic Screening of Anti-tumor Agents.RETRACTED: NAD(P)H:quinone oxidoreductase 1 protects lungs from oxidant-induced emphysema in mice.An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.Upregulation of NAD(P)H:quinone oxidoreductase by radiation potentiates the effect of bioreductive beta-lapachone on cancer cells.Quinone reductases multitasking in the metabolic world.Beta-lapachone-containing PEG-PLA polymer micelles as novel nanotherapeutics against NQO1-overexpressing tumor cellsTargeting glutamine metabolism sensitizes pancreatic cancer to PARP-driven metabolic catastrophe induced by ß-lapachoneEfficacious fluorescence turn-on probe for high-contrast imaging of human cells overexpressing quinone reductase activity.Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachone.Fibulin-5 Blocks Microenvironmental ROS in Pancreatic Cancer.PRX1 knockdown potentiates vitamin K3 toxicity in cancer cells: a potential new therapeutic perspective for an old drug.Depleting Tumor-NQO1 Potentiates Anoikis and Inhibits Growth of NSCLC.Nuclear ULK1 promotes cell death in response to oxidative stress through PARP1Superparamagnetic iron oxide nanoparticles: amplifying ROS stress to improve anticancer drug efficacy.
P2860
Q24805337-B78EB0EF-5DCC-42B7-8E3D-5393E8CBDDF0Q26823209-18721799-D5C0-437D-AE83-A1F31EE90D88Q27346846-CC82C351-BF5E-4634-AAF6-535AF9E1015FQ28274858-CB18FF1C-FE8B-416B-A3A0-ABF8D71BC48CQ28383361-FE98BCDA-541D-4705-9695-09571A514B36Q28391294-365C51BF-31D8-4BE7-B815-653F5C059831Q28474095-B9E72D3E-C794-4D0B-93EB-D7BB76BCCE3AQ28481323-435541C8-2945-4352-B913-0AE6D1892DAAQ28482133-798BCF6D-0E16-4B61-BA4C-BBCDE7889677Q28539534-1BC79C98-A967-43F9-9FF3-18D8F3185DCEQ28730305-96F294A9-AF6D-467B-8842-6FC5D8F3CD82Q28741474-FB0730CE-FCDF-47A5-976B-399E8DB11862Q30872924-C6034784-3E15-4A82-BDE6-5B4EC99231C1Q31037843-1D0F7694-02A6-4BB5-93E4-E5B02B4CFBDDQ33708518-0852DECC-6BB9-4F3D-8CA9-6925B0BB6089Q33753357-526F7F4B-62B7-4B96-A13F-960B733A7C04Q33767952-069853F1-CF0C-41F0-967A-5A197CC44A9DQ33862927-04A57B91-3CF0-4C8F-9160-32FA6DB37487Q33955000-693F8EB4-B98B-4376-8EC1-944B60C85D7AQ34026936-3264B63A-B6DC-4E53-AEA4-3F1634A797B7Q34047248-0641A7F4-287E-41A8-A5A5-772512285038Q34447919-E44EA4E2-9EB7-43EE-926C-DA011A8DDEAFQ34654289-5BF922DB-7DA9-4AB0-9216-C2403D39BC65Q34807961-C48F7D18-571F-4313-8D3C-D2D29551B5C8Q35032472-29D23A18-63E6-4230-9F71-8DC9E95B7D9CQ35239089-2E10676C-D61B-4740-A260-BEE585027696Q35593948-CF58CC36-43E4-4F60-B415-2F72C27BC334Q35705835-76CB704F-82DF-4654-966F-C1F9C3C5DA61Q35880201-AB25530C-A02F-435E-BC9A-0AD6E6D3641DQ35945059-F3521F77-B9C4-4A85-936F-F6D43CFACD45Q35956182-79E8253E-0830-43DA-9E1B-4846969FF3F1Q36119847-CC46E374-3F70-4ECE-83C5-B4F9B7EC59AAQ36146939-DC312491-61B7-40B3-A0FA-CC42A9D0C9EFQ36230143-6622177B-48FD-4089-B74E-2316F3259715Q36316513-09741E86-5A8C-4E0D-B8EF-7DDD98A8735FQ36342854-2163F673-D129-4CB6-8D23-40047C5D3A9CQ36393755-663DD237-7739-4B96-831F-AD9A41611E23Q36471467-6D05F183-7D62-4443-A005-73011BC727BFQ36472478-E5CF8521-30B7-4032-80B1-85921E787FE9Q36619072-F9DEFF9C-2F8A-4E62-8380-A65F86F4A891
P2860
NAD(P)H:Quinone oxidoreductase activity is the principal determinant of beta-lapachone cytotoxicity.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh
2000年學術文章
@zh-hant
name
NAD(P)H:Quinone oxidoreductase ...... f beta-lapachone cytotoxicity.
@en
type
label
NAD(P)H:Quinone oxidoreductase ...... f beta-lapachone cytotoxicity.
@en
prefLabel
NAD(P)H:Quinone oxidoreductase ...... f beta-lapachone cytotoxicity.
@en
P2093
P2860
P356
P1476
NAD(P)H:Quinone oxidoreductase ...... f beta-lapachone cytotoxicity.
@en
P2093
C Tagliarino
D A Boothman
M E Varnes
S M Planchon
P2860
P304
P356
10.1074/JBC.275.8.5416
P407
P577
2000-02-01T00:00:00Z